The Spinal Cord Injury drugs in development market research report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Spinal Cord Injury. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued products.

GlobalData tracks 103 drugs in development for Spinal Cord Injury by 93 companies/universities/institutes. The top development phase for Spinal Cord Injury is preclinical with 66 drugs in that stage. The Spinal Cord Injury pipeline has 87 drugs in development by companies and 16 by universities/ institutes. Some of the companies in the Spinal Cord Injury pipeline products market are: AXONIS Therapeutics, SanBio and Axoltis Pharma.

The key targets in the Spinal Cord Injury pipeline products market include Reticulon 4 (Human NogoA or Neurite Outgrowth Inhibitor or Foocen or Neuroendocrine Specific Protein or Neuroendocrine Specific Protein C Homolog or RTN x or Reticulon 5 or RTN4), Receptor Type Tyrosine Protein Phosphatase S (Receptor Type Tyrosine Protein Phosphatase Sigma or R PTP Sigma or PTPRS or EC 3.1.3.48), and Repulsive Guidance Molecule A (RGM Domain Family Member A or RGMA).

The key mechanisms of action in the Spinal Cord Injury pipeline product include Reticulon 4 (Human NogoA or Neurite Outgrowth Inhibitor or Foocen or Neuroendocrine Specific Protein or Neuroendocrine Specific Protein C Homolog or RTN x or Reticulon 5 or RTN4) Inhibitor with three drugs in Phase II. The Spinal Cord Injury pipeline products include 14 routes of administration with the top ROA being Intravenous and 18 key molecule types in the Spinal Cord Injury pipeline products market including Cell Therapy, and Small Molecule.

Spinal Cord Injury overview

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida, or Friedreich’s ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head, or back; paralysis in any part of the body; numbness, tingling, or loss of sensation in the hands, fingers, feet, or toes; loss of bladder or bowel control; difficulty in walking; and impaired breathing after injury.

For a complete picture of Spinal Cord Injury’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.